NASDAQ · ABBV
Healthcare · Drug Manufacturers - General
$261.72
Up+$1.71 (+0.66%)
Updated Sep 3, 2026, 6:25 AM
SID Score
7.1/10
Composite research score
Smart Money
54/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
ABBV closed at $261.72 after 21 trading sessions, up 6.30% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 2, 2026 | $262.70 | $262.97 | $257.70 | $261.72 | 4.23M |
| Sep 1, 2026 | $260.99 | $262.265 | $257.79 | $259.99 | 3.87M |
| Aug 31, 2026 | $254.17 | $258.24 | $252.33 | $256.42 | 4.32M |
| Aug 28, 2026 | $258.67 | $259.00 | $255.0797 | $255.48 | 3.22M |
| Aug 27, 2026 | $260.81 | $262.4977 | $257.25 | $258.15 | 4.76M |
| Aug 26, 2026 | $264.60 | $265.00 | $260.31 | $262.90 | 3.31M |
| Aug 25, 2026 | $264.50 | $266.905 | $263.025 | $265.79 | 3.67M |
| Aug 24, 2026 | $263.99 | $266.0395 | $262.07 | $264.52 | 3.88M |
| Aug 21, 2026 | $260.70 | $266.84 | $260.101 | $264.96 | 5.16M |
| Aug 20, 2026 | $265.69 | $265.93 | $260.4812 | $261.83 | 5.23M |
| Aug 19, 2026 | $261.51 | $266.965 | $259.55 | $265.97 | 5.54M |
| Aug 18, 2026 | $253.93 | $259.18 | $252.41 | $258.92 | 5.01M |
| Aug 17, 2026 | $249.49 | $251.49 | $248.31 | $250.33 | 4.65M |
| Aug 14, 2026 | $250.60 | $250.61 | $247.68 | $249.46 | 4.2M |
| Aug 13, 2026 | $252.94 | $255.295 | $249.35 | $250.82 | 4.37M |
| Aug 12, 2026 | $245.98 | $250.09 | $245.52 | $248.76 | 3.78M |
| Aug 11, 2026 | $248.14 | $250.765 | $247.18 | $250.09 | 4.49M |
| Aug 10, 2026 | $245.65 | $248.01 | $244.03 | $247.97 | 4.21M |
| Aug 7, 2026 | $243.62 | $246.76 | $241.95 | $246.04 | 4.93M |
| Aug 6, 2026 | $249.04 | $249.95 | $241.20 | $243.87 | 4.57M |
| Aug 5, 2026 | $247.00 | $249.38 | $243.76 | $246.20 | 5.19M |
The latest Smart Investors Daily articles mentioning ABBV.
ABBV research
Company profile and research snapshot.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | Piper Sandler | Overweight | — |
| Aug 17, 2026 | Wells Fargo | Overweight | — |
| Aug 13, 2026 | Wolfe Research | Outperform | — |
| Aug 11, 2026 | BNP Paribas | Neutral | — |
| Aug 10, 2026 | Evercore ISI Group | Outperform | — |
Generated Sep 2, 2026, 9:00 PM
AbbVie shares gained 0.66% today as the company continues to benefit from its strong dividend reputation and positioning within healthcare's secular growth trends. The modest uptick reflects renewed investor interest in ABBV's dividend-paying profile amid discussions of big pharma's resurgence and the aging population's healthcare demands.
Bottom line: AbbVie's modest daily gain reflects its dual appeal as a dividend stock and big pharma play positioned to benefit from secular healthcare trends and potential sector rotation. However, investors should monitor political developments around drug pricing and await the Wells Fargo conference presentation for guidance on managing regulatory headwinds while maintaining dividend sustainability.
Yahoo · Sep 2, 2026
Most retirees assume hitting a $68,400 annual income floor demands either a massive nest egg or risky high-yield instruments, but five ordinary dividend stocks across five sectors challenge both assumptions in ways the math makes hard to ignore.
Yahoo · Sep 2, 2026
Kymera Therapeutics' (KYMR) KT-621 could validate its "oral Dupixent" potential, but with a roughly
Yahoo · Sep 2, 2026
Allergan Aesthetics, an AbbVie company, today unveiled the Layered Beauty: The New Aesthetic Mindset report, informed by research among more than 12,000 beauty-involved consumers across nine global markets, complemented by practitioner expertise and regional perspectives. The report provides a global perspective on the impact of cultural attitudes toward beauty and aging to evolve the aesthetic treatment landscape and offers healthcare providers new perspectives on the behaviors shaping today's
SeekingAlpha · Sep 2, 2026
Clinuvel Pharmaceuticals Limited analysis: SCENESSE profits, A$252M cash/no debt, and CUV105 vitiligo trial catalyst vs AbbVie/Pfizer risksâclick for more on CUVL.
Interpretive context generated from the platform’s current data sources.
AbbVie Inc. shares closed at $259.99, declining 1.32% in the most recent session, per SID market data. Despite the daily pullback, the stock has demonstrated strong momentum over intermediate timeframes, gaining 20.42% over the trailing three months and 12.12% over the past year. The shares currently trade above both key moving averages, with the 50-day moving average at $252.57 and the 200-day moving average at $227.18, reflecting a sustained uptrend. AbbVie's 14-day relative strength index stands at 57.6, indicating neutral momentum without overbought or oversold conditions. The stock's beta of 0.334, according to Massive/Polygon data, signals significantly lower volatility relative to the broader market, consistent with its defensive healthcare positioning. Average daily trading volume is approximately 6.4 million shares, supporting a market capitalization of $410.1 billion, placing AbbVie among the largest biopharmaceutical companies globally.
AbbVie Inc. currently trades at a price-to-earnings ratio of 97.75, a notably elevated multiple relative to the broader healthcare sector, per SID market data. This high P/E ratio reflects the earnings impact from significant amortization and acquisition-related charges tied to AbbVie's extensive deal history. The PEG ratio stands at 1.25, suggesting a more moderate valuation when accounting for projected earnings growth. The company's price-to-book ratio registers as negative at -126.33, a result of accumulated goodwill write-downs and substantial share repurchase activity that has driven book value below zero, according to SEC filings. AbbVie maintains a dividend yield of 2.87%, reinforcing its status as a reliable income-generating holding in the pharmaceutical space. The company's negative tangible book value is not uncommon among large-cap pharma firms that have pursued aggressive acquisition strategies, and investors have historically focused on cash flow generation rather than book value as the primary valuation anchor.
AbbVie Inc. carries a composite smart money score of 54, reflecting a neutral overall signal, per SID market data. The institutional sub-score registers a perfect 25 out of 25, indicating exceptionally strong positioning among major fund managers and institutional investors, according to 13F institutional filings. The insider trading sub-score is also elevated at 18 out of 25, supported by two insider transactions recorded in the last 90 days — both of which were purchases with zero insider sales reported during the period, per SEC Form 4 filings. This buy-only insider pattern suggests management confidence in AbbVie's forward trajectory. Offsetting these bullish signals, the dark pool activity sub-score is relatively subdued at 9.8 out of 25, indicating limited off-exchange accumulation by large block traders. Congressional trading activity is minimal at 0.8 out of 25, showing virtually no notable positions taken by members of Congress. The divergence between strong institutional and insider conviction versus muted dark pool and congressional interest creates the overall neutral composite reading.
AbbVie Inc. has delivered mixed earnings results across its recent quarterly reports. In the most recently completed quarter, the company reported earnings per share of $2.65 against a consensus estimate of $2.66, resulting in a marginal miss of $0.01, according to company earnings reports. The prior quarter showed a positive surprise, with actual EPS of $2.71 exceeding the $2.66 estimate by $0.05. Looking ahead, analysts project EPS of $3.01 for the upcoming quarter ending in early 2026, per analyst estimates. The forward quarter carries an estimate of $3.77, though the most recent result for that period showed actual EPS of $3.65, representing a miss of $0.12. This pattern of narrow misses in recent periods indicates tightening margins relative to consensus expectations. The sequential progression from $2.65 to an estimated $3.01 and $3.77 reflects anticipated earnings growth, driven in part by AbbVie's expanding immunology and oncology portfolios beyond its legacy Humira franchise.
Wall Street analyst sentiment toward AbbVie Inc. is predominantly constructive, per SID consensus data. In the most recent coverage updates, Piper Sandler reiterated its Overweight rating on August 20, 2026, while Wells Fargo similarly maintained its Overweight stance on August 17, according to Wall Street analyst reports. Notably, Wolfe Research upgraded ABBV to Outperform from Peer Perform on August 13, representing the most significant rating change during the period and reflecting growing confidence in AbbVie's commercial execution. BNP Paribas maintained a Neutral rating on August 11, serving as the sole non-bullish voice among recent coverage. Evercore ISI Group reiterated its Outperform rating on August 10. Of the five most recent analyst actions, four carry bullish designations — either Overweight or Outperform — with one Neutral and zero bearish ratings. The Wolfe Research upgrade is particularly noteworthy as it signals a shift from a relative-value framework to an absolute conviction call on the stock's upside potential.
The latest Smart Investors Daily articles mentioning ABBV.
